{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T13:11:19Z","timestamp":1775308279213,"version":"3.50.1"},"reference-count":55,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>As of September 2021, twenty-one anti-COVID-19 vaccines have been approved in the world. Their utilization will expedite an end to the current pandemic. Besides the usual vaccine formats that include inactivated viruses (eight approved vaccines) and protein-based vaccines (four approved vaccines), three new formats have been validated: recombinant adenovirus (six approved vaccines), DNA (one approved vaccine), and messenger RNA (mRNA, two approved vaccines). The latter was the fastest (authorized in 2020 in the EU, the USA, and Switzerland). Most Western countries have reserved or use the protein vaccines, the adenovirus vaccines, and mRNA vaccines. I describe here the different vaccine formats in the context of COVID-19, detail the three formats that are chiefly reserved or used in Europe, Canada, and the USA, and discuss why the mRNA vaccines appear to be the superior format.<\/jats:p>","DOI":"10.3390\/cells10102716","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T09:16:42Z","timestamp":1633943802000},"page":"2716","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Vaccines against COVID-19: Priority to mRNA-Based Formulations"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2946-5576","authenticated-orcid":false,"given":"Steve","family":"Pascolo","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital of Z\u00fcrich, Raemistrasse 100, 8091 Z\u00fcrich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1517\/14712598.4.8.1285","article-title":"Messenger RNA-based vaccines","volume":"4","author":"Pascolo","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1385\/1-59745-168-1:23","article-title":"Vaccination with messenger RNA","volume":"127","author":"Pascolo","year":"2006","journal-title":"DNA Vaccines"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-3-540-72167-3_11","article-title":"Vaccination with messenger RNA (mRNA)","volume":"Volume 183","author":"Bauer","year":"2008","journal-title":"Toll-Like Receptors (TLRs) and Innate Immunity. Handbook of Experimental Pharmacology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1586\/14760584.2015.1000871","article-title":"The messenger\u2019s great message for vaccination","volume":"14","author":"Pascolo","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_5","first-page":"6937","article-title":"Messenger RNA: The inexpensive biopharmaceutical","volume":"4","author":"Pascolo","year":"2017","journal-title":"J. Multidiscip. Eng. Sci. Technol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytesin vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"ref_7","first-page":"1397","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#","article-title":"In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies","volume":"30","author":"Hoerr","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Wu, S., Huang, J., Zhang, Z., Wu, J., Zhang, J., Hu, H., Zhu, T., Zhang, J., Luo, L., and Fan, P. (2021). Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: Preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect. Dis., 10, Online ahead of print.","DOI":"10.1016\/S1473-3099(21)00396-0"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.chom.2021.08.002","article-title":"An AAV-based, room-temperature stable, single dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates","volume":"29","author":"Zabaleta","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"109493","DOI":"10.1016\/j.celrep.2021.109493","article-title":"Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding","volume":"36","author":"Trimpert","year":"2021","journal-title":"Cell Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2102775118","DOI":"10.1073\/pnas.2102775118","article-title":"Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy","volume":"118","author":"Wang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","first-page":"e2026207118","article-title":"Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination","volume":"118","author":"Tscherne","year":"2021","journal-title":"bioRxiv"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1006\/plas.1997.1329","article-title":"Genetically engineered vaccines: An overview","volume":"39","author":"Dertzbaugh","year":"1998","journal-title":"Plasmid"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and Efficacy of NVX-CoV2373 COVID-19 Vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/13543776.18.3.293","article-title":"Adenovirus-vectored vaccines","volume":"18","author":"Chawla","year":"2008","journal-title":"Expert Opin. Ther. Patents"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9987","DOI":"10.1128\/JVI.00751-10","article-title":"Chromosomal integration of adenoviral vector DNA in vivo","volume":"84","author":"Stephen","year":"2010","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0140-6736(20)32623-4","article-title":"Oxford\u2013AstraZeneca COVID-19 vaccine efficacy","volume":"397","author":"Knoll","year":"2021","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1\u20132a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1517\/14712598.5.7.919","article-title":"HLA class I transgenic mice: Development, utilisation and improvement","volume":"5","author":"Pascolo","year":"2005","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1084\/jem.185.12.2043","article-title":"HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice","volume":"185","author":"Pascolo","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1479-0556-4-4","article-title":"Characterization of the ribonuclease activity on the skin surface","volume":"4","author":"Probst","year":"2006","journal-title":"Genet. Vaccines Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.gt.3302964","article-title":"Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent","volume":"14","author":"Probst","year":"2007","journal-title":"Gene Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1007\/s00018-004-4255-0","article-title":"Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines","volume":"61","author":"Carralot","year":"2004","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/eji.200324198","article-title":"Immunostimulating capacities of stabilized RNA molecules","volume":"34","author":"Scheel","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/eji.200425656","article-title":"Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA","volume":"35","author":"Scheel","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/mt.2010.289","article-title":"Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients","volume":"19","author":"Rittig","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/CJI.0b013e31815ce501","article-title":"Results of the first phase I\/II clinical vaccination trial with direct injection of mRNA","volume":"31","author":"Weide","year":"2008","journal-title":"J. Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","article-title":"Direct injection of protamine-protected mRNA: Results of a phase 1\/2 vaccination trial in metastatic melanoma patients","volume":"32","author":"Weide","year":"2009","journal-title":"J. Immunother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: The COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100766","DOI":"10.1016\/j.nantod.2019.100766","article-title":"Three decades of messenger RNA vaccine development","volume":"28","author":"Verbeke","year":"2019","journal-title":"Nano Today"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1002\/cpz1.39","article-title":"Cap 1 messenger RNA Synthesis with Co-transcriptional CleanCap\u00ae analog by in vitro transcription","volume":"1","author":"Henderson","year":"2021","journal-title":"Curr. Protoc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1093\/nar\/12.18.7035","article-title":"Efficientin vitrosynthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter","volume":"12","author":"Melton","year":"1984","journal-title":"Nucleic Acids Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/eji.200635910","article-title":"Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA","volume":"36","author":"Scheel","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"van Doremalen, N., Fischer, R.J., Schulz, J.E., Holbrook, M.G., Smith, B.J., Lovaglio, J., Petsch, B., and Munster, V.J. (2021). Immunogenicity of low-dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates. Viruses, 13.","DOI":"10.1101\/2021.07.07.451505"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA Recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Buckstein","year":"2005","journal-title":"Immunity"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"14630","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/ni.2169","article-title":"Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus","volume":"13","author":"Honke","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_52","first-page":"616","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Naaber, P., Tserel, L., Kangro, K., Sepp, E., J\u00fcrjenson, V., Adamson, A., Haljasm\u00e4gi, L., Rumm, A.P., Maruste, R., and K\u00e4rner, J. (2021). Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study. Lancet Reg. Health-Eur., 100208. in press.","DOI":"10.1016\/j.lanepe.2021.100208"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Haas, E.J., McLaughlin, J.M., Khan, F., Angulo, F.J., Anis, E., Lipsitch, M., Singer, S.R., Mircus, G., Brooks, N., and Smaja, M. (2021). Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer\u2013BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: A retrospective surveillance study. Lancet Infect. Dis., 10, online ahead of print.","DOI":"10.2139\/ssrn.3845367"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/10\/2716\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:11:33Z","timestamp":1760166693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/10\/2716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":55,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["cells10102716"],"URL":"https:\/\/doi.org\/10.3390\/cells10102716","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]}}}